Comparison of plasma and tissue levels of ZDI 694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models
1998

Study of ZD1694 (Tomudex) Levels in Plasma and Tissues

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): GW Aherne, E Ward, N Lawrence, D Dobinson, SJ Clarke, H Musgrove, F Sutcliffe, T Stephens, AL Jackman

Primary Institution: CRC Centre for Cancer Therapeutics, Institute of Cancer Research

Hypothesis

The study investigates the pharmacokinetics and tissue distribution of ZD1694 (Tomudex) in preclinical models.

Conclusion

ZD1694 is rapidly eliminated from plasma but accumulates significantly in tissues, suggesting its effectiveness as a thymidylate synthase inhibitor.

Supporting Evidence

  • ZD1694 was measured in plasma and tissues, showing high tissue to plasma ratios.
  • The drug was rapidly eliminated from plasma but retained in tissues for extended periods.
  • Total drug levels in liver, kidney, and gut epithelium were significantly higher than in plasma.
  • High tissue concentrations were maintained for at least 7 days in mice and 28 days in dogs.

Takeaway

This study shows that a cancer drug called ZD1694 leaves the blood quickly but stays in the body’s tissues for a long time, which might help it work better against cancer.

Methodology

The study used a sensitive radioimmunoassay to measure ZD1694 levels in plasma and tissues of mice and dogs after administration.

Limitations

The study could not measure individual polyglutamated forms of ZD1694.

Participant Demographics

Mice and dogs were used as preclinical models.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication